Annual occurring and averted DALYs in 2035
| In millions | |||||
| State | No intervention (CI) | 20% reduction (CI) | Difference (CI) | 50% reduction (CI) | Difference (CI) |
| NASH | 2.97 (2.955–2.988) | 2.76 (2.746–2.777) | 0.210 (0.209–0.212) | 2.32 (2.309–2.334) | 0.650 (0.645–0.655) |
| Cirrhosis | 0.48 (0.475–0.482) | 0.42 (0.422–0.428) | 0.053 (0.053–0.054) | 0.31 (0.312–0.316) | 0.164 (0.162–0.165) |
| HCC | 3.06 (3.046–3.084) | 2.78 (2.765–2.799) | 0.283 (0.279–0.283) | 2.19 (2.180–2.206) | 0.872 (0.863–0.881) |
| CHD | 2.32 (2.305–2.330) | 2.29 (2.276–2.302) | 0.028 (0.028–0.029) | 2.23 (2.217–2.242) | 0.088 (0.086–0.090) |
| T2D | 8.21 (8.180–8.248) | 8.06 (8.023–8.089) | 0.158 (0.155–0.160) | 7.72 (7.690–7.752) | 0.492 (0.487–0.498) |
| Obesity | 0.69 (0.689–0.700) | 0.66 (0.655–0.666) | 0.034 (0.034–0.035) | 0.59 (0.584–0.593) | 0.106 (0.105–0.107) |
| Total | 17.74 (17.65–17.83) | 16.97 (16.89–17.06) | 0.767 (0.757–0.777) | 15.37 (15.29–15.44) | 2.372 (2.348–2.396) |
| From mortality | 11.94 | 11.50 | 0.439 | 10.58 | 1.357 |
| From morbidity | 5.80 | 5.47 | 0.328 | 4.78 | 1.015 |
CHD, coronary heart disease; CI, 95% central coverage interval; DALY, disability-adjusted life year; HCC, hepatocellular carcinoma; NASH, non-alcoholic steatohepatitis; T2D, type 2 diabetes.
Numbers might not add up due to rounding.